Latest news with #SrikripaDevarakonda
Business Insider
5 days ago
- Business
- Business Insider
Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $53.00. Confident Investing Starts Here: According to TipRanks, Devarakonda is an analyst with an average return of -5.9% and a 32.60% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Regeneron, and Scholar Rock Holding. In addition to Truist Financial, Kymera Therapeutics also received a Buy from Citi's Geoff Meacham in a report issued today. However, yesterday, Morgan Stanley maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
Reuters
6 days ago
- Business
- Reuters
Regeneron's weight-loss drug combo helps preserve muscle in study
June 2 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday a combination of its experimental drug and Novo Nordisk's ( opens new tab obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage trial. The combination of Regeneron's drug, trevogrumab, and Wegovy helped preserve up to 51.3% of the lean mass after 26 weeks, compared with 34.5% loss when Wegovy was administered alone, according to interim data from the 599-patient study. The results mark an early win for Regeneron as it races against a dozen companies to develop obesity treatments that preserve muscle, as they seek to find the next breakthrough in the potential $150 billion weight-loss drug market. Blockbuster weight-loss drugs from Novo Nordisk and Eli Lily (LLY.N), opens new tab have helped patients shed fat, but also led to muscle loss that can increase the risk of falls and decrease overall strength, which could be especially harmful for older patients. Wegovy helped patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass, while the combination of Regeneron's trevogrumab and Wegovy led to weight loss of about 21.6 pounds, with only 3.7 pounds in lean mass. "While we wait for detailed data, we believe that these data give a glimpse into the potential for these drugs to preserve muscle," said Truist analyst Srikripa Devarakonda. Meanwhile, a triple combination of Novo's semaglutide, Regeneron's trevogrumab and experimental antibody garetosmab led to a substantially higher rate of discontinuation due to tolerability issues and other side effects, Regeneron said. The full data set will be available later this year, the drugmaker said. Regeneron on Monday announced a licensing deal worth up to $2.01 billion with China's Hansoh Pharmaceuticals ( opens new tab for an experimental obesity drug.
Medscape
6 days ago
- Business
- Medscape
Regeneron's Weight-loss Drug Combo Helps Preserve Muscle in Study
(Reuters) -Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped patients lose weight while preserving lean muscle mass in a mid-stage trial. The combination of Regeneron's drug, trevogrumab, and Wegovy helped preserve up to 51.3% of the lean mass after 26 weeks, compared with 34.5% loss when Wegovy was administered alone, according to interim data from the 599-patient study. The results mark an early win for Regeneron as it races against a dozen companies to develop obesity treatments that preserve muscle, as they seek to find the next breakthrough in the potential $150 billion weight-loss drug market. Blockbuster weight-loss drugs from Novo Nordisk and Eli Lily have helped patients shed fat, but also led to muscle loss that can increase the risk of falls and decrease overall strength, which could be especially harmful for older patients. Wegovy helped patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass, while the combination of Regeneron's trevogrumab and Wegovy led to weight loss of about 21.6 pounds, with only 3.7 pounds in lean mass. "While we wait for detailed data, we believe that these data give a glimpse into the potential for these drugs to preserve muscle," said Truist analyst Srikripa Devarakonda. Meanwhile, a triple combination of Novo's semaglutide, Regeneron's trevogrumab and experimental antibody garetosmab led to a substantially higher rate of discontinuation due to tolerability issues and other side effects, Regeneron said. The full data set will be available later this year, the drugmaker said. Regeneron on Monday announced a licensing deal worth up to $2.01 billion with China's Hansoh Pharmaceuticals for an experimental obesity drug. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber and Shinjini Ganguli)
Reuters
27-01-2025
- Health
- Reuters
Veru's experimental drug helps older obese patients on Wegovy preserve muscle
Jan 27 (Reuters) - Veru (VERU.O), opens new tab said on Monday its experimental drug in combination with Novo Nordisk's ( opens new tab weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage study. Shares of the drug developer, however, fell 44% to 67 cents in morning trading as patients receiving Veru's drug and Wegovy did not shed more pounds compared to those on Wegovy and placebo. The company also did not disclose safety data from the study. "We believe weight loss of the combined drugs and safety are (the) key metrics investors are looking for," Truist Securities analyst Srikripa Devarakonda said, adding that Veru's data "attempts to address the importance of muscle preservation." Patients on Veru's oral drug, enobosarm, and Wegovy lost 71% less lean muscle on average than those who received placebo and Wegovy over 16 weeks. Those who received the enobosarm and Wegovy combination lost more fat mass, Veru said. Veru, Eli Lilly (LLY.N), opens new tab, Regeneron (REGN.O), opens new tab and Scholar Rock (SRRK.O), opens new tab are among the several drugmakers aiming to help obesity patients improve the quality of their weight loss while preserving muscle mass and losing more fat. Enobosarm was tested in 168 overweight or obese patients aged 60 years and above, who are at a greater risk of falls and fractures. The drug targets the androgen receptors present in skeletal muscle and play a role in body development. About 19% of the patients on enobosarm and Wegovy lost at least 10% of their power to climb stairs - fewer than the 42.6% of patients on Wegovy alone who experienced a similar or greater loss. Veru will test the effects of its drug on stair climb power as the main goal in a larger study. It is also testing whether enobosarm can prevent the fat and weight regain that can occur once patients stop taking Wegovy in an extension study. It plans to disclose safety details in April, once the extension study is completed.
